· 13 sources · Verified
CoFlo Medical raises $6M to tackle a drug-delivery bottleneck
CoFlo surrounds thick medicines with a thinner liquid to ease injection. Pharmaceutical partners still need a product that delivers the right dose reliably.
By Venture Capital Tracker
For a drug developer, shrinking an injection can create an engineering problem: a concentrated medicine may become harder to push through a needle. CoFlo Medical surrounds it with a thinner liquid to reduce that resistance. The commercial challenge is turning the technique into a finished drug product.
Deal details & investors
Funding event
CoFlo Medical
Led by J2 Ventures
CEO Simon Rufer announced the seed financing on November 19. J2 Ventures separately confirmed that it leads the round. The San Francisco company's ambition is to help move suitable treatments from intravenous infusions towards injections under the skin, potentially in a doctor's office or at home.
The sources reviewed do not identify a CoFlo-enabled medicine approved for that proposed home use. A partner would need evidence that the medicine stays stable, the device delivers the right dose and people can use it reliably.
What travels through the needle
CoFlo's technique, called core annular flow, keeps the thick medicine in the centre and a thinner fluid against the needle wall.
The surrounding fluid is part of the injection. CoFlo's technical FAQ says it must be chemically and biologically compatible with the medicine; one option is the medicine's own saline buffer. It mixes with the drug after delivery. Reducing resistance does not by itself establish stability, compatibility or the clinical performance of a particular formulation.
The company's designs put that fluid in different places. The Gen One stores it in the needle hub, which connects to a prefilled syringe. The Double Barrel holds the two fluids in separate syringes and feeds them through a connecting CO-AXL hub.
Those details matter commercially. They determine which containers and preparation steps a pharmaceutical team would need to evaluate, alongside the drug itself.
Promising measurements, with specific limits
The scientific starting point predates the latest funding. A 2020 paper in Advanced Healthcare Materials reported up to a sevenfold reduction in force for the highest viscosity ratio tested. Co-founders Vishnu Jayaprakash and Kripa Varanasi were among its authors.
A September 2026 technical article by Rufer and CoFlo engineer Pratik Mishra describes a later demonstration. A 2-millilitre model liquid with a viscosity of 800 centipoise passed through a 27-gauge thin-wall needle in 20 seconds, using less than 20 newtons of force. Its illustration specifies a 12% saline sheath by volume. The authors report a 100-fold reduction in force against a conventional device under their test conditions.
This is a laboratory result using a model liquid, not evidence that a patient can take any medicine at home in 20 seconds. The sevenfold and 100-fold figures come from different experiments and should not be treated as a directly comparable improvement series.
The same company-authored article describes an exploratory usability exercise with 12 first-time lay users, who completed filling, connection and delivery steps using instructions. It offers early information about handling. It does not establish a finished product's clinical efficacy or replace product-specific human-factors validation.
What a pharmaceutical partner would have to test
Consider a developer evaluating a concentrated antibody medicine for injection under the skin. The following is an illustrative VCT diligence sequence, not a report of a CoFlo customer trial.
First, agree what must be delivered: the dose, concentration, needle, target time and total volume, including the sheath. Then test whether the two fluids remain compatible and whether the device reliably delivers the intended dose.
Next, test the preparation and injection steps: who connects the parts, how they recognise completion and what happens after an incomplete dose. FDA's September 2023 final guidance on human factors for combination products addresses critical tasks and evaluation with intended users in the expected use environment. It distinguishes studies of the user interface from clinical studies of safety and effectiveness.
Manufacturing and shelf life also belong in the evaluation. FDA's October 2026 draft guidance on essential drug-delivery performance discusses testing, continued performance over shelf life and manufacturing controls. Its injector examples include dose accuracy, injection time and completion feedback. It remains draft guidance, not a final rule or an approval determination for CoFlo.
For a partner, the practical question is whether those pieces can be demonstrated for the proposed medicine and complete device, at a cost and development timetable it can accept.
Other approaches address different constraints
Drug developers can also work on how liquid spreads through tissue or how a larger dose is administered. Those approaches address different constraints.
| Approach | What its supplier describes | What the developer still needs to evaluate |
|---|---|---|
| CoFlo core annular flow | A compatible sheath fluid reduces resistance inside the needle. | Drug–sheath compatibility, total injected volume and the selected device configuration. |
| Halozyme ENHANZE | An enzyme temporarily breaks down hyaluronan, a tissue component, under the skin, helping fluid dispersion and absorption. | Suitability of the co-administered drug and enzyme combination. |
| Enable enFuse | A wearable system delivers larger-volume injections under the skin, with vial or syringe transfer options. | The complete drug-device configuration and its preparation and wearing workflow. |
Needle resistance, tissue dispersion and administration volume are different problems. These approaches can address overlapping constraints; the descriptions reviewed do not provide a head-to-head clinical comparison establishing a universal winner.
What the financing does—and does not—establish
The announced round is US$6 million. An earlier SEC Form D recorded a $6 million equity offering with $500,000 sold and a first sale on November 5, 2025. That is an earlier snapshot of fundraising, not another $500,000 to add to the new announcement. The relationship between the filing and the November 2026 total has not been fully disclosed.
The current announcements do not establish a valuation, complete investor list, legal closing date or how much of the total represents newly received cash in November. J2's investment thesis is that easier administration could expand access and reduce the burden of treatment; those are anticipated benefits, not measured outcomes from the financing.
In Brian Gormley's November 19 Wall Street Journal reporting, Rufer described seeking a pharmaceutical co-development partnership. The sources reviewed did not establish public pricing, licence terms, product revenue or a named co-development agreement.
A prospective partner therefore has three concrete questions for CoFlo: which medicine would they develop together, what evidence remains to be generated and who pays for that work?
Follow Venture Capital Tracker on Google
Add VCT as a preferred source to see more of our venture-capital reporting in Google Search.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.